The BEACON study (breast cancer outcomes with NKTR-102)

The BC Cancer Agency has designed a randomized controlled trial for patients with metastatic breast cancer. The trial seeks to uncover the effects of adding NKTR-102 once every 3 weeks to a patient's existing intravenous chemotherapy regimen. More information on this trial can be found here.